Search results
2022. Articles 1–20. Duke University, Pratt School of Engineering - Cited by 1,946 - Biomedical Engineering & Neuroscience.
Michael Tadross, MD, PhD, is an Assistant Professor of Biomedical Engineering and Neurobiology at Duke University, where he develops genetically encoded technologies to target clinically relevant drugs to specific cell types in the brain.
Michael Tadross. Assistant Professor of Biomedical Engineering at Duke University. I received a B.S. in Electrical & Computer Engineering with a minor in Chemistry at Rutgers; an M.D.-Ph.D. in Biomedical Engineering at Johns Hopkins; and postdoctoral training in Cellular Neuroscience at Stanford.
Oct 23, 2018 · Aiming to address this gap, Michael Tadross, MD, PhD, a biomedical engineer at Duke University, and his team have developed DART — Drugs Acutely Restricted by Tethering. This method works by genetically programming a cell type to express a sort of GPS beacon — a cell surface receptor protein called HaloTag.
- Managing Science Editor
Michael Tadross, assistant professor of biomedical engineering at Duke University, has been chosen as a recipient of the competitive 2017 Parkinson's Foundation Stanley Fahn Junior Faculty Award. Managed by the Parkinson's Foundation Grants Review Committee, the new program supports junior faculty at a critical time of career transition.
DART.3-Revolutionizing Neuropsychiatric Treatment through Noninvasive, Programmable Cell-Type-Specific Neuropharmacology. Research Principal Investigator · Awarded by National Institutes of Health · 2024 - 2027.
Leadership & Staff. Michael Raphael Tadross. Assistant Professor of Biomedical Engineering. Dr. Tadross' lab develops technologies to rapidly deliver drugs to genetically defined subsets of cells in the brain.
